Skip to main content

Table 1 Characteristics of included patients from COHERE 2010–2014 and EuroSIDA 2001–2016

From: Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016

  All
n (% of all)a
Late presenters
n (% of LP)b
Total number of people included 39,204 (100) 18,967 (48.4)
Mode of infection
 Sex between men 20,061 (51.2) 7712 (38.4)
 Sex between men and women - men 6262 (16.0) 3915 (62.5)
 Sex between men and women - women 6400 (16.3) 3529 (55.1)
 Injecting drug use - men 1293 (3.3) 753 (58.2)
 Injecting drug use - men 401 (1.0) 165 (41.2)
 Men other 3304 (8.4) 2006 (60.7)
 Women other 1483 (3.8) 887 (59.8)
Region of residence
 West 38,511 (98.2) 18,629 (48.4)
 Central (EuroSIDA only) 179 (0.5) 115 (64.2)
 East (EuroSIDA only) 514 (1.3) 223 (43.4)
Region of birth
 Europe 25,746 (65.0) 11,773 (46.2)
 Africa 3666 (9.4) 2345 (64.0)
 Other 3670 (9.4) 2005 (54.6)
 Unknown 6392 (16.3) 2844 (44.5)
Cohort
 COHERE 2010–2014 38,511 (98.2) 18,629 (48.4)
 EuroSIDA 2001–2016 693 (1.8) 338 (48.8)
  median (IQR) median (IQR)
Age (years) 37 (29–45) 39 (32–48)
CD4 cell count at entry into COHERE/EuroSIDA (/mm3) 365 (186–553) 180 (70–272)
Baseline† (month/year) 10/2011 (11/2010–11/2012) 09/2011 (11/2010–11/2012)
  1. Countries included from EuroSIDA: Central Europe: Poland. Eastern Europe: Belarus, Estonia, Russia, Ukraine. † Baseline was defined as the earliest of positive HIV test, first study visit or cohort enrolment. apercentage is a column percentage. bpercentage is a row percentage